Psoriasis Pipeline Update  JNJ2113 A Novel Oral IL23 Receptor Antagonist Peptide Shows Promise in a Phase 2b Study thumbnail
Media formats available:
Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free